Celularity Sales Trend Ahead of Views for Q1; Plans SG&A Cuts, Manufacturing Ramp

 Expects the First Quarter of 2024 will be the 4^th consecutive quarter of both sequential and quarter-on-quarter net sales growth

Implements plan to reduce 2024 selling, general & administrative expenses (SG&A), executive cash compensation, reinforces management’s alignment of incentives with shareholders on corporate success

https://www.biospace.com/article/releases/celularity-announces-net-sales-trending-ahead-of-expectations-for-first-quarter-2024-implements-planned-2024-sg-and-a-reductions-and-manufacturing-ramp-for-advanced-biomaterial-products/